OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC

August 10th 2023

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast Cancer

August 10th 2023

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.

Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer

August 10th 2023

Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.

Dr Barroilhet on the Role of PARP Inhibitors in BRCA+ and HRD Ovarian Cancer

August 10th 2023

Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.

Dr Hays on Unmet Needs in CRC

August 10th 2023

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.

Dr Halpern on the MANIFEST Trial of Pelabresib and Ruxolitinib in Myelofibrosis

August 10th 2023

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCC

August 10th 2023

Shawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).

Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer

August 9th 2023

Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.

Dr Fonkoua on Alternatives to Platinum Chemotherapy in Cancer Care

August 9th 2023

Lionel A. Kankeu Fonkoua, MD, discusses challenges arising from the ongoing shortage of platinum chemotherapy in the United States and suggests potential alternatives to cisplatin that may benefit patients with cancer during this shortage.

Dr Manana on How Systemic Racism Appears in Oncology

August 9th 2023

Ana I. Velazquez Manana, MD, MSc, discusses how systemic racism appears in oncology.

Dr Cecchini on the Results of the PROSPECT Trial in Rectal Cancer

August 9th 2023

Michael Cecchini, MD, discusses the phase 3 PROSPECT trial of neoadjuvant chemoradiation vs neoadjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy with selective use of chemoradiation, followed by total mesorectal excision in patients with locally advanced rectal cancer, and how this regimen may fit into the current treatment landscape for rectal cancer.

Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer

August 9th 2023

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

August 9th 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC

August 9th 2023

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

Dr Massarelli on Effectively Treating Patients During the United States Chemotherapy Shortage

August 8th 2023

Erminia Massarelli MD, PhD, MS, discusses strategies created by City of Hope to effectively navigate the treatment of patients with lung cancer during the platinum chemotherapy shortage in the United States.

Dr Patel on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

August 8th 2023

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

Dr Danish on the Potential for Treatment with SCINTIX Radiation Technology in Lung and Bone Cancers

August 8th 2023

Adnan F. Danish, MD, discusses the potential for SCINTIX radiation technology to open new treatment opportunities for patients with cancer, including those with lung and bone cancers, whose disease has metastasized to more than 5 sites.

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

August 8th 2023

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

Dr Santos on Steps Taken to Address the Chemotherapy Shortage in the United States

August 8th 2023

Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.

Dr Peters on the Steps Being Taken to Address Chemotherapy Shortages in Cancer Care

August 7th 2023

Solange Peters, MD, PhD, discusses steps being taken to address the ongoing platinum chemotherapy shortage in the United States for patients with cancer.